SFX by Ex Libris Inc.

Title:	Reovirus therapy of tumors with activated Ras pathway
Source:	Science [0036-8075] Coffey, M C yr:1998

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Arnberg, N. "Adenovirus receptors: implications for tropism, treatment and targeting." Reviews in medical virology 19.3 (2009): 165-178.
description	2.	Aoki Y, Y. "The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders." Human mutation 29.8 (2008): 992-1006.
description	3.	Vidal, L. "A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer." Clinical cancer research 14.21 (2008): 7127-7137.
description	4.	Smith, E R R. "Oncolytic viruses as novel anticancer agents: turning one scourge against another." Expert opinion on investigational drugs 9.2 (2000): 311-327.
description	5.	Shmulevitz, M. "Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer." Oncogene 24.52: 7720-7728.
description	6.	White, C L L. "Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial." Gene therapy 15.12 (2008): 911-20.
description	7.	Mita, M. "Reovirus-based therapy for cancer." Expert Opinion on Biological Therapy 9.7 (2009): 817-30.
description	8.	Gelb, Bruce D D. "Noonan syndrome and related disorders: Dysregulated RAS-mitogen activated protein kinase signal transduction." Human molecular genetics 15.SUPPL. 2 (2006): 220-6.
description	9.	Tidyman, William E E. "Noonan, Costello and cardio-facio-cutaneous syndromes : dysregulation of the Ras-MAPK pathway." Expert reviews in molecular medicine 10 (2008).
description	10.	Kalyuzhniy, O., Di Paolo, N. C., Silvestry, M., Ho, O. "Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo." Proceedings of the National Academy of Sciences of the United States of America 105.14: 5483-8.
description	11.	Gaggar, A. "CD46 is a cellular receptor for group B adenoviruses." Nature medicine 9.11 (2003): 1408-1412.
description	12.	Echavarría, M. "Adenoviruses in immunocompromised hosts." Clinical microbiology reviews 21.4 (2008): 704-15.
description	13.	Shirakawa, T. "The Current Status of Adenovirus-based Cancer Gene Therapy." Molecules and cells 25.4 (2008): 462-6.
description	14.	Kerr, B. "The diagnosis of Costello syndrome: Nomenclature in Ras/MAPK pathway disorders." American journal of medical genetics. Part A 146A.9 (2008): 1218-20.
description	15.	Parato, Kelley A. "Recent progress in the battle between oncolytic viruses and tumours." Nature reviews. Cancer 5.12 (2005): 965-76.
description	16.	P, M. "Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release." Molecular therapy 15.8 (2007): 1522-1530.
description	17.	Johnston, Randal N N. "Reovirus and tumor oncolysis." The journal of microbiology 45.3 (2007): 187-92.
description	18.	El Khordagui, Labiba K. K. "Microneedles: An emerging approach for active transdermal delivery of insulin." Journal of bioequivalence and bioavailability 5.1 (2013): 1-.
description	19.	Russo, Grazia E. "Melanoma: molecular pathogenesis and emerging target therapies (Review)." International journal of oncology 34.6 (2009): 1481-9.
description	20.	Markert, J. "Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial." Gene therapy 7.10 (2000): 867-874.